Outcomes of long term treatments of type I hereditary angioedema in a Turkish family

ArticleAçık Erişim

Özet

Background: Hereditary angioedema is a rare autosomal dominantly inherited immunodeficiency disorder characterized by potentially life-threatening angioedema attacks. Objective: We aimed to investigate the clinical and genetic features of a family with angioedema attacks. Methods: The medical history, clinical features and C1-INH gene mutation of a Turkish family were investigated and outcomes of long-term treatments were described. Results: Five members had experienced recurrent swellings on the face and extremities triggered by trauma. They were all misdiagnosed as familial Mediterranean fever (FMF) depending on frequent abdominal pain and were on colchicine therapy for a long time. They had low C4 and C1-INH protein concentrations and functions. A mutation (c.1247T>A) in C1-INH gene was detected. They were diagnosed as having hereditary angioedema with C1-INH deficiency (C1-INH hereditary angioedema) for the first time. Three of them benefited from danazol treatment without any significant adverse events and one received weekly C1 esterase replacement treatment instead of danazol since she had a medical history of thromboembolic stroke. Study limitations: Small sample size of participants. Conclusion: Patients with C1-INH hereditary angioedema may be misdiagnosed as having familial Mediterranean fever in regions where the disorder is endemic. Medical history, suspicion of hereditary angioedema and laboratory evaluations of patients and their family members lead the correct diagnoses of hereditary angioedema. Danazol and C1 replacement treatments provide significant reduction in hereditary angioedema attacks. © 2017 by Anais Brasileiros de Dermatologia.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/14778Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorAkoglu, Gulsen
dc.contributor.authorYildiz, Gokhan
dc.contributor.authorKesim, Belgin
dc.contributor.authorMetin, Ahmet
dc.date.accessioned2026-10-18T20:29:34.903589395Z
dc.date.available2026-10-18T20:29:34.903589395Z
dc.date.issued2017
dc.description.abstractBackground: Hereditary angioedema is a rare autosomal dominantly inherited immunodeficiency disorder characterized by potentially life-threatening angioedema attacks. Objective: We aimed to investigate the clinical and genetic features of a family with angioedema attacks. Methods: The medical history, clinical features and C1-INH gene mutation of a Turkish family were investigated and outcomes of long-term treatments were described. Results: Five members had experienced recurrent swellings on the face and extremities triggered by trauma. They were all misdiagnosed as familial Mediterranean fever (FMF) depending on frequent abdominal pain and were on colchicine therapy for a long time. They had low C4 and C1-INH protein concentrations and functions. A mutation (c.1247T>A) in C1-INH gene was detected. They were diagnosed as having hereditary angioedema with C1-INH deficiency (C1-INH hereditary angioedema) for the first time. Three of them benefited from danazol treatment without any significant adverse events and one received weekly C1 esterase replacement treatment instead of danazol since she had a medical history of thromboembolic stroke. Study limitations: Small sample size of participants. Conclusion: Patients with C1-INH hereditary angioedema may be misdiagnosed as having familial Mediterranean fever in regions where the disorder is endemic. Medical history, suspicion of hereditary angioedema and laboratory evaluations of patients and their family members lead the correct diagnoses of hereditary angioedema. Danazol and C1 replacement treatments provide significant reduction in hereditary angioedema attacks. © 2017 by Anais Brasileiros de Dermatologia.
dc.identifier.doi10.1590/abd1806-4841.20175899
dc.identifier.eissn1806-4841
dc.identifier.endpage660
dc.identifier.issn0365-0596
dc.identifier.issue5
dc.identifier.pmcidPMC5674698
dc.identifier.pmid29166502
dc.identifier.scopus2-s2.0-85034964305
dc.identifier.startpage655
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/14778
dc.identifier.volume92
dc.identifier.wosWOS:000416001300009
dc.language.isoen
dc.publisherSociedade Brasileira de Dermatologia
dc.relation.ispartofAnais Brasileiros de Dermatologia
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectComplement C1 inhibitor protein
dc.subjectDanazol
dc.subjectHereditary Angioedema Types I and II
dc.subjectAdult
dc.subjectAngioedemas, Hereditary
dc.subjectBase Sequence
dc.subjectChild
dc.subjectEstrogen Antagonists
dc.subjectFemale
dc.subjectGene Amplification
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMutation
dc.subjectPedigree
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.subjectTurkey
dc.subjectcolchicine
dc.subjectcomplement component C1s inhibitor
dc.subjectfresh frozen plasma
dc.subjectantiestrogen
dc.subjectabdominal pain
dc.subjectangioneurotic edema
dc.subjectArticle
dc.subjectcase report
dc.subjectclinical article
dc.subjectdiagnostic error
dc.subjectdrug dose reduction
dc.subjectfamilial Mediterranean fever
dc.titleOutcomes of long term treatments of type I hereditary angioedema in a Turkish family
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus3
rdl.citation.wos3
rdl.departmentMedical Biology, Faculty of Medicine, Erzincan University- Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)